Dermatology

Combination therapy outperformed excimer light alone for vitiligo, according to Giovanni Leone, MD.

Bempikibart use led to clinically meaningful SALT improvements among those with alopecia areata in the phase 2a SIGNAL-AA study at 36 weeks.

In this podcast episode, 2 featured experts discuss AI, teledermatology, and strategies to reduce bias in skin of color dermatologic care.

As July is UV Safety Awareness Month, key tips for addressing sun damage, skin cancer signs, photoaging, and more are highlighted in this discussion.

Martin discussed where hydroquinone still fits, why oral tranexamic acid remains underused, and how he decides when to escalate to procedural therapy.

In this Q&A interview, Davinder Parsad, MD, highlights vitiligo misconceptions and upcoming news in the vitiligo treatment pipeline.

In this Q&A, Hilary Baldwin, MD, discusses common misperceptions, the current pipeline, and how she separates rosacea from acne.

This week’s headlines include the FDA acceptance of mitapivat and roflumilast applications, the approval of atacicept for IgA nephropathy, and more.

At Maui Derm NP+PA Summer 2026, Benjamin Ungar, MD, discussed early clues for scarring alopecia, pipeline JAK inhibitors, and setting patient expectations.

During her SDPA Conference interview, Murase gave several more tips for skin management during pregnancy.

In this SDPA interview, Murase provides tips for clinicians on conversations related to pregnancy, safety, and skin disease management.

Topical ruxolitinib shows sustained repigmentation over years, while oral JAK inhibitors move toward approval for widespread disease, George Martin, MD, says.

This Q&A interview highlights Katta's views on dietary and nutritional supplements' impact on skin health as well as their long-term effects.

This review highlights some of the most notable stories covered by the HCPLive team within the first half of 2026.

At Maui Derm Summer 2026, Hilary Baldwin, MD, used a single theoretical patient to illustrate how rosacea subtypes evolve and how treatment should follow suit.

At Maui Derm NP+PA Summer 2026, Benjamin Ungar, MD, detailed how JAK inhibitors and oral minoxidil are reshaping hair loss treatment strategy.

This review highlights the most notable dermatology news stories covered by HCPLive during the second quarter of 2026.

Frieden discusses somatic mutations driving vascular malformations and how repurposed cancer therapies like alpelisib and sirolimus are changing care.

Rajani Katta, MD, an author and dermatologist, spoke regarding her SDPA session on diet and its connection to dermatology.

This interview highlights both key findings and the significance of the POSITIVE trial for clinicians and for individuals with psoriasis.

This review of June 2026 headlines covers the most notable stories in dermatology, including FDA news, new data, and podcast updates.

This interview segment from SDPA highlights insights on hormonal impacts on dermatology as well as other key highlights from sessions at the meeting.

A review of 9 novel drugs approved by the US Food and Drug Administration during the second quarter of 2026.

This interview at the SDPA Summer Conference highlights key myths and how to address them as a clinician in dermatology.

A review of 22 novel drugs approved by the US Food and Drug Administration during the first half of 2026, with links to coverage from MJH Life Sciences publications.